Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978398790> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2978398790 endingPage "S12" @default.
- W2978398790 startingPage "S12" @default.
- W2978398790 abstract "Purpose: This study compared the effect on basal and pentagastrin stimulated acid output (BAO and PAO) of single-dose i.v. administration of esomeprazole 40 mg and omeprazole 40 mg. Methods: This was an open, randomized, two-way cross-over study in 23 Helicobacter pylori-negative healthy male and female subjects (18 males; mean age: 26 years; mean body mass index: 22.8 kg/m). Both drugs were administered as single 30-minute i.v. infusions with a washout period of at least 6 days. BAO (1 h) and PAO (1.5 hrs) were determined at baseline, between 3–5.5 h and finally between 23–25.5 h after drug administration on each study day. Blood samples, taken during the first 12 hours, were used to determine the area under the plasma concentration-time curve (AUC) and maximum observed plasma concentration (Cmax) for both drugs. The PAO and BAO values were analyzed using a mixed model ANOVA. The mean for each treatment and the mean treatment difference were estimated with 95% confidence intervals (CI). As an interim analysis was performed when 12 subjects had been included in the study, a 97.5% CI was calculated for the mean difference in PAO measured 3-5.5 hours after dose. Results: At baseline the mean BAO and PAO were 4.4 mmol/h (95% CI: 3.0 to 5.8) and 34.0 mmol/h (95% CI: 30.2 to 37.2), respectively. Intravenous administration of esomeprazole 40 mg resulted in a more pronounced reduction in BAO and PAO both measured 3–5.5 h and 23–25.5 h after dose compared with omeprazole 40 mg i.v. (Table). The geometric mean AUC and Cmax values were 36% and 18% higher, respectively, for esomeprazole 40 mg i.v. compared with omeprazole 40 mg i.v. There were no serious adverse events and both drugs were well tolerated.Table: Basal and pentagastrin stimulated acid output (BAO, PAO).Conclusions: Esomeprazole 40 mg i.v. provides faster and more complete control of basal and stimulated gastric acid secretion throughout the 24-hour period than omeprazole 40 mg i.v." @default.
- W2978398790 created "2019-10-10" @default.
- W2978398790 creator A5017040666 @default.
- W2978398790 creator A5022464609 @default.
- W2978398790 creator A5060438926 @default.
- W2978398790 creator A5083124928 @default.
- W2978398790 creator A5090288748 @default.
- W2978398790 date "2004-10-01" @default.
- W2978398790 modified "2023-10-14" @default.
- W2978398790 title "ESOMEPRAZOLE 40 MG ADMINISTERED INTRAVENOUSLY (I.V.) PROVIDES BETTER CONTROL OF BASAL AND STIMULATED GASTRIC ACID SECRETION THAN OMEPRAZOLE 40 MG ADMINISTERED I.V." @default.
- W2978398790 doi "https://doi.org/10.14309/00000434-200410001-00033" @default.
- W2978398790 hasPublicationYear "2004" @default.
- W2978398790 type Work @default.
- W2978398790 sameAs 2978398790 @default.
- W2978398790 citedByCount "0" @default.
- W2978398790 crossrefType "journal-article" @default.
- W2978398790 hasAuthorship W2978398790A5017040666 @default.
- W2978398790 hasAuthorship W2978398790A5022464609 @default.
- W2978398790 hasAuthorship W2978398790A5060438926 @default.
- W2978398790 hasAuthorship W2978398790A5083124928 @default.
- W2978398790 hasAuthorship W2978398790A5090288748 @default.
- W2978398790 hasConcept C112705442 @default.
- W2978398790 hasConcept C126322002 @default.
- W2978398790 hasConcept C22979827 @default.
- W2978398790 hasConcept C2777498785 @default.
- W2978398790 hasConcept C2777504413 @default.
- W2978398790 hasConcept C2778024521 @default.
- W2978398790 hasConcept C2778204628 @default.
- W2978398790 hasConcept C2779306644 @default.
- W2978398790 hasConcept C2779377912 @default.
- W2978398790 hasConcept C2779422922 @default.
- W2978398790 hasConcept C42219234 @default.
- W2978398790 hasConcept C44249647 @default.
- W2978398790 hasConcept C71924100 @default.
- W2978398790 hasConcept C90924648 @default.
- W2978398790 hasConcept C99476002 @default.
- W2978398790 hasConceptScore W2978398790C112705442 @default.
- W2978398790 hasConceptScore W2978398790C126322002 @default.
- W2978398790 hasConceptScore W2978398790C22979827 @default.
- W2978398790 hasConceptScore W2978398790C2777498785 @default.
- W2978398790 hasConceptScore W2978398790C2777504413 @default.
- W2978398790 hasConceptScore W2978398790C2778024521 @default.
- W2978398790 hasConceptScore W2978398790C2778204628 @default.
- W2978398790 hasConceptScore W2978398790C2779306644 @default.
- W2978398790 hasConceptScore W2978398790C2779377912 @default.
- W2978398790 hasConceptScore W2978398790C2779422922 @default.
- W2978398790 hasConceptScore W2978398790C42219234 @default.
- W2978398790 hasConceptScore W2978398790C44249647 @default.
- W2978398790 hasConceptScore W2978398790C71924100 @default.
- W2978398790 hasConceptScore W2978398790C90924648 @default.
- W2978398790 hasConceptScore W2978398790C99476002 @default.
- W2978398790 hasLocation W29783987901 @default.
- W2978398790 hasOpenAccess W2978398790 @default.
- W2978398790 hasPrimaryLocation W29783987901 @default.
- W2978398790 hasRelatedWork W1985302117 @default.
- W2978398790 hasRelatedWork W2010073807 @default.
- W2978398790 hasRelatedWork W2050172625 @default.
- W2978398790 hasRelatedWork W2055101668 @default.
- W2978398790 hasRelatedWork W2084064692 @default.
- W2978398790 hasRelatedWork W2095142232 @default.
- W2978398790 hasRelatedWork W2113690245 @default.
- W2978398790 hasRelatedWork W2412414089 @default.
- W2978398790 hasRelatedWork W3137331026 @default.
- W2978398790 hasRelatedWork W4253354477 @default.
- W2978398790 hasVolume "99" @default.
- W2978398790 isParatext "false" @default.
- W2978398790 isRetracted "false" @default.
- W2978398790 magId "2978398790" @default.
- W2978398790 workType "article" @default.